Head to head

CJC-1295 without DAC vs GHRP-2

GH secretagogue

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Usually stacked — and only GHRP-2 has human trial data

CJC-1295 without DAC and GHRP-2 appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you are picking one, the evidence is the honest tiebreak: GHRP-2 has approval from a regulator somewhere, though not a current FDA or EMA label, while CJC-1295 without DAC has no controlled human data at all, so the numbers here come from practice, not a label. That is a difference in how much is known, not a verdict on how well either works.

What you are actually choosing between

Before anything else: the dataset lists CJC-1295 without DAC and GHRP-2 in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is recovery and sleep and muscle growth. On this site's goal weighting — an editorial priority score, not a measure of effect size — CJC-1295 without DAC rates 4/5 for recovery and sleep and GHRP-2 rates 3/5. Outside that overlap only GHRP-2 goes further, carrying weight for appetite control; CJC-1295 without DAC's declared goals stop at the overlap.

The evidence

This is the part that decides most of it. GHRP-2 has approval from a regulator somewhere, though not a current FDA or EMA label — registered in Japan as pralmorelin for a single-dose diagnostic test, not chronic use. CJC-1295 without DAC has no controlled human data at all, so the numbers here come from practice, not a label — the closest approved comparators are sermorelin and tesamorelin. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

How they differ in practice

CJC-1295 without DAC is a subcutaneous injection; GHRP-2 is a subcutaneous injection and an intramuscular injection. Both are injected, so route does not decide this one.

Half-lives are close — 30 min for CJC-1295 without DAC, 1 h for GHRP-2 — and both are dosed once daily, so the rhythm of actually running them is the same.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

CJC-1295 without DAC (Mod GRF 1-29)

Tetra-substituted GHRH (1-29) with no Drug Affinity Complex, so it clears in roughly 30 minutes and produces a single discrete GH pulse. That short half-life is the whole point: it is dosed once to three times daily, typically around 100 mcg (roughly 1-2 mcg/kg, a saturating pulse dose) on an empty stomach, and is paired with a ghrelin agonist such as ipamorelin. It is NOT an approved medicine; the closest approved comparators are sermorelin and tesamorelin. Consumer supply is research-chemical grade and dosing convention comes from practice, not from a label.

GHRP-2

Synthetic hexapeptide ghrelin receptor (GHS-R1a) agonist. Unusually for this corner of the market it has real human data: it has been studied as a growth hormone secretagogue in published dose-response work, and the same molecule is registered in Japan as pralmorelin for use as a single-dose diagnostic test of growth hormone deficiency. That diagnostic use is a one-off intravenous challenge, not a chronic subcutaneous protocol, so the human evidence supports the fact that it releases growth hormone rather than the community habit of dosing it daily for months. It is not approved for physique or anti-ageing use anywhere. It is less selective than ipamorelin: expect measurable prolactin and cortisol elevation, which is the usual reason people switch away from it. The 100-300 mcg per dose range, often split into two or three doses a day, comes from practice rather than from a label.

Side by side

The numbers

CJC-1295 without DAC compared with GHRP-2
Attribute	CJC-1295 without DAC	GHRP-2
Class	GH secretagogue	GH secretagogue
Routes	Subcutaneous	Subcutaneous, Intramuscular
Dose range	100 mcg–300 mcg (typical 100 mcg)	100 mcg–300 mcg (typical 200 mcg)
Frequency	Once daily	Once daily
Half-life	30 min	1 h
Cycle length	12 weeks	12 weeks
Experience	Intermediate	Intermediate
Evidence	Practice-derived only	Approved elsewhere
Contraindications	Pregnant / nursing Active malignancy Under 18	Pregnant / nursing Active malignancy Under 18
Side effects	Injection site redness, itching or a short-lived welt Head rush, flushing or warmth in the minutes after injection Mild water retention Tingling or numbness in the hands Drowsiness when dosed pre-bed	Raises prolactin and cortisol more than ipamorelin does — this is its main practical drawback, and it scales with dose, so pushing past roughly 300 mcg per injection buys little extra growth hormone while making the hormonal spillover worse Hunger spike within about half an hour of dosing, which works against a cut Water retention, morning puffiness, and numb or tingling hands Head rush, flushing or brief light-headedness just after injection Blunted response over months of uninterrupted daily use, so it is usually cycled Injection site redness or itching

Turn a typical dose into a mark on the syringe: CJC-1295 without DACGHRP-2

Goals

Where they overlap, and where they do not

Goal	CJC-1295 without DAC	GHRP-2
recovery and sleep	CJC-1295 without DAC: 4/5	GHRP-2: 3/5
muscle growth	CJC-1295 without DAC: 3/5	GHRP-2: 3/5
injury repair	CJC-1295 without DAC: 3/5	GHRP-2: 2/5
fat loss	CJC-1295 without DAC: 2/5	GHRP-2: 2/5
longevity	CJC-1295 without DAC: 2/5	GHRP-2: 1/5
appetite controlone only	CJC-1295 without DAC: —	GHRP-2: 3/5

They overlap on 5 goals and diverge on 1. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCJC-1295 without DAC (Mod GRF 1-29)Mechanism, protocol, storage, sources.MonographGHRP-2Mechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.